Upfront Briefing
Wednesday is catalyst-watch day. Moderna's flu shot — the one CBER refused to file back in February — walks into a June 18 FDA panel that's less about safety than whether the trial design holds up. The briefing docs poke at efficacy in the 50-plus crowd but skip the dire flags.
Lilly, meanwhile, kept its deal machine idling in the pain aisle with an undisclosed, all-cash grab of MNK-inhibitor shop 4E — another small, early bet in a year full of them. Policy tape stayed noisy too; biotech rarely gets just one flavor of volatility.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,511.4 |
(0.6%) |
9.5% |
| Nasdaq 100 |
29,968.1 |
(1.9%) |
18.9% |
| Russell 2000 |
2,939.2 |
(0.9%) |
17.2% |
| Healthcare (XLV) |
152.9 |
0.0% |
(1.7%) |
| Biotech (XBI) |
135.3 |
(0.8%) |
11.4% |
| Nasdaq Biotech (NBI) |
5,953.3 |
(0.4%) |
4.3% |
| Clinical Trials (BBC) |
43.0 |
(1.4%) |
16.0% |
|
- Biotech leaned defensive into a down tape — XLV flat, XBI off 0.8%, NBI down 0.4%, all better than the Nasdaq 100 — with Moderna (MRNA) in focus ahead of Wednesday's VRBPAC flu panel and Lilly's 4E buy keeping the non-opioid pain trade live.
- Macro split ahead of the June 16–17 Fed decision: the Dow printed a record as money rotated to defensives, while the Nasdaq 100 (1.9%) and Russell 2000 (0.9%) backslid — with no cut priced and hike odds creeping up, higher-for-longer keeps derating growth.
- Market data: U.S. cash close Tuesday, 16 June 2026.
The Big 3
|
1
|
Moderna flu shot faces FDA scrutiny before June 18 adcomm
|
- mRNA-1010, Moderna's seasonal flu vaccine, heads into the June 18 adcomm with mixed FDA briefing-doc readthroughs: no major red flags cited, but the supporting evidence is under scrutiny.
-
Why it matters: mRNA-1010 — now MFLUSIVA — is the asset CBER refused to file in February over trial design, so Wednesday's VRBPAC is less a science test than a regulatory-rehab one, with an Aug 5 PDUFA already on the clock. Briefing docs flag efficacy questions in the 50-plus accelerated-approval cohort but no safety dealbreaker — the difference between a clean panel and a delay. Flu is the second respiratory leg Moderna needs to hit its ~$1.9B 2026 revenue target and salvage a 2028 breakeven the RTF blew open; a ~$1B product hangs on the vote. Watch the older-adult data and the required post-marketing study — that's where the friction lands.
- Source: Fierce Biotech
- More: BioPharma Dive; BioSpace;
|
|
2
|
Lilly buys non-opioid pain shop 4E in another early-stage bolt-on
|
-
Lilly is acquiring Austin-based 4E Therapeutics for undisclosed terms, adding oral MNK inhibitors (lead 4ET1103, Phase 1-cleared) that target chronic pain via peripheral sensory neurons — no CNS, no opioid liability.
-
Why it matters: Lilly's playbook here is volume — a string of small, early-stage neuro and pain bets where, as Dave Van Naarden put it, most won't work but the few that do cover the basket. 4ET1103 rhymes with last year's up-to-$1B SiteOne grab (NaV1.8) and sits in the lane Vertex's Journavx just commercialized. Undisclosed terms tell you the data's early and the check is small. The read for private pain developers: there's a live, repeat buyer writing on Phase 1 assets.
-
Source:
BioPharma Dive
-
More:
Fierce Biotech;
PR Newswire;
|
|
3
|
Merck writes another AI-discovery check — $510M biobucks for Protillion
|
-
Merck signed a $510M biobucks collaboration and license with AI protein-design shop Protillion, taking its Prot-MaP data-generation platform — undisclosed upfront plus R&D and commercial milestones across multiple undisclosed programs.
-
Why it matters: Protillion lands Merck as validation for Prot-MaP — $510M in biobucks, though the undisclosed upfront tells you most of that is milestone optionality on unnamed programs. The real read is on Merck: this is the fourth AI-discovery check it's written in months, after a $1B Google Cloud build-out, $838M to Infinimmune on antibodies, and $20M to Quotient in IBD. A patent-cliff giant facing Keytruda LOE in 2028 is buying discovery speed it can't build internally fast enough. For the AI-protein names, it's another sign pharma will pay for the platform layer, not just finished molecules — but biobucks rarely pay in full, so discount the headline.
-
Source:
Fierce Biotech
-
More:
Business Wire;
|
Everything Else that broke
- FDA cleared Colorado's drug-import plan from Canada, though launch timing remains unclear. — FDA — Endpoints
- BioCentury said Democratic drug-pricing proposals could build on existing policy and pressure industry revenues. — BioCentury
- Health groups criticized HHS over a rushed ACIP reinstatement process after the panel freeze. — STAT — Endpoints
- Express Scripts and PCMA sued to block Tennessee's PBM-pharmacy breakup law. — BioPharma Dive
- Edgewise's EDG-7500 posted 12-week CIRRUS-HCM Phase 2 data (KCCQ +13 in nonobstructive HCM, no LVEF drops below 50%), keeping it on track for Phase 3 against BMS's Camzyos and Cytokinetics' Myqorzo; shares fell ~10% on the narrower efficacy gap before recovering. — Fierce Biotech
- Be Bio halted a hemophilia B trial, cutting one clinical proof point for its B-cell therapy platform. — Fierce Biotech — Endpoints
- Akeso reported Phase II ligufalimab combination data in frontline AML with deep responses and a survival-benefit claim. — PR
- NMD Pharma shared Phase 2a ignaseclant data in Charcot-Marie-Tooth disease at the PNS meeting. — PR
- Jazz highlighted real-world Xywav data showing cardiometabolic marker changes in sleep disorders. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Lilly acquired 4E Therapeutics for its non-opioid pain pipeline; terms undisclosed (see The Big 3). — BioPharma Dive
- Merck and Protillion inked a $510M biobucks AI drug-discovery collaboration and license (Prot-MaP platform); undisclosed upfront (see The Big 3). — Fierce Biotech
- Altaris is taking Simulations Plus private for $375M, merging the AI drug-development software maker with Chemical Computing Group. — Fierce Biotech
- Rigel closed its global VEPPANU (vepdegestrant) license from Arvinas/Pfizer — $70M upfront, up to $320M in milestones; launch slated for August. — PR Newswire
VC / Private Financings
- No notable VC / private financings in the last 24 hours.
IPOs / Follow-Ons
- SOPHiA GENETICS (SOPH) priced a $50M follow-on — 10,526,000 ordinary shares at $4.75, TD Cowen lead, 30-day option on 1.58M more; closes June 18. — PR Newswire
|
